ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol

ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol

Introduction Sepsis is a major cause of death among hospitalised patients. Accumulating evidence suggests that immune response during sepsis cascade lies within a spectrum of dysregulated host responses. On the one side of the spectrum there are patients whose response is characterised by fulminant...

Full description

Saved in:
Bibliographic Details
Main Authors: Peter Pickkers, Evangelos J Giamarellos-Bourboulis, Mihai G Netea, Michael Bauer, Mihaela Lupse, Frank Bloos, Tom van der Poll, W Joost Wiersinga, Thierry Calandra, Sylvain Meylan, Alexander P J Vlaar, Sebastian Weis, Marleen A Slim, Niels van Mourik, Marcella C A Müller, Antigone Kotsaki, Lonneke van Vught, Aline de Nooijer, Lieke Bakkerus, Nikolaos Antonakos
Format: Article
Language:English
Published: BMJ Publishing Group 2022-12-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/12/e067251.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items